Cationic arginine-rich and poly-arginine peptides (referred to as CARPs) have potent neuroprotective properties in in vitro excitotoxicity and in vivo models of stroke. Traumatic brain injury (TBI) shares many pathophysiological processes as stroke, including excitotoxicity. Therefore, we evaluated our lead peptide, poly-arginine R18, with the COG1410 and APP96-110 peptides, which have neuroprotective actions following TBI. In an in vitro cortical neuronal glutamic acid excitotoxicity injury model, R18 was highly neuroprotective and reduced neuronal calcium influx, while COG1410 and APP96-110 displayed modest neuroprotection and were less effective at reducing calcium influx. In an impact-acceleration closed-head injury model (Marmarou model), R18, COG1410, and APP96-110 were administered intravenously (300 nmol/kg) at 30 minutes after injury in male SpragueDawley rats. When compared to vehicle, no peptide significantly improved functional outcomes, however the R18 and COG1410 treatment groups displayed positive trends in the adhesive tape test and rotarod assessments. Similarly, no peptide had a significant effect on hippocampal neuronal loss, however a significant reduction in axonal injury was observed for R18 and COG1410. In conclusion, this study has demonstrated that R18 is significantly more effective than COG1410 and APP96-110 at reducing neuronal injury and calcium influx following excitotoxicity, and that both R18 and COG1410 reduce axonal injury following TBI. Additional dose response and treatment time course studies are required to further assess the efficacy of R18 in TBI.
Introduction
Neuroprotective pharmacological agents aimed at minimising harm to the brain and improving patient outcomes after a traumatic brain injury (TBI) are currently lacking. As such, TBI places a massive burden on society and the economy, a situation further compounded by its rising incidence [1] . Current surgical and rehabilitative interventions are limited in their ability to improve outcomes caused by TBI, and a large proportion of survivors endure debilitating neurological deficits as a consequence [2] .
With limited efficacious treatment options, the development of an effective neuroprotective agent would be of great clinical significance in terms of reducing the impact of TBI on patients and the wider community.
Our laboratory has demonstrated that cationic arginine-rich peptides including polyarginine peptides (hereafter referred to as CARPs) have potent neuroprotective properties in an in vitro glutamic acid excitotoxicity neuronal injury model [3] [4] [5] [6] , as well as in vivo after both permanent and transient middle cerebral artery occlusion (MCAO) stroke in rats [4, [7] [8] [9] [10] . Furthermore, increasing arginine content and positive charge are critical for peptide neuroprotective potency (Meloni et al., 2015a) , with poly-arginine peptide R18 identified as our lead peptide (18-mer of arginine; Table 1 ). The COG1410 and APP96-110 peptides are derived from the apolipoprotein E and amyloid precursor proteins, respectively, and have been demonstrated to improve outcomes in several acute brain injury models, including TBI [11] [12] [13] [14] [15] [16] [17] [18] . Interestingly, both COG1410 and APP96-110 are also cationic and arginine-rich (Table 1 ).
In view of the involvement of excitotoxicity in secondary central nervous system injury cascades, and the pathophysiological parallels between stroke and TBI, it is likely that CARPs could also have beneficial effects following TBI [19, 20] . Therefore, we assessed our lead peptide, R18, along with the COG1410 and APP96-110 peptides in an in vitro glutamic acid neuronal excitotoxicity injury model and an in vivo impact-acceleration TBI model.
ASSESSMENT OF R18, COG1410, AND APP96-110 IN EXCITOTOXICITY AND TRAUMATIC BRAIN INJURY Methods

Peptides used in this study
Details of the peptides used in this study are provided in Table 1 . Peptides for this study were synthesised by Mimotopes (Australia) and purified by high performance liquid chromatography. For both in vitro and in vivo studies, peptides were respectively prepared as a 500 µM stock solution in water for irrigation (Baxter, Australia), and in 0.9% sodium chloride for injection (Pfizer, Australia). Reconstituted peptides were stored at -20°C until use.
Primary cortical neuronal cultures
The isolation and culturing of primary cortical neurons was undertaken as previously described [3] . Briefly, cortical tissue extracted in real time using a fluorescent plate reader, as previously described [5] . Table 2 
Functional assessments
Due to the exploratory nature of the study, three behavioural tests (Barnes maze, adhesive tape removal, and rotarod) were assessed to measure potential injury deficits. These assessments were carried out daily, starting at 24 hours after surgery and continued until study end-point (4 days post-TBI). Each animal was given three attempts at each test, and the first attempt was used for statistical analyses.
The Barnes maze is a well-characterised spatial learning and memory test [22] that utilises a rat's innate need to escape brightly-lit areas. Animals are required to find the location of an escape hole from 20 other holes set in a round Histological assessment for axonal injury and hippocampal neuronal loss 
Results
Effect of peptides on cultured neurons exposed to glutamic acid excitotoxicity
The neuroprotective dose response efficacy of R18, COG1410, and APP96-110 peptides was compared in cortical neuronal cultures exposed to glutamic acid excitotoxicity ( Figure   1 ). As previously reported [5] , R18 was highly Effect of peptides on histological outcomes following TBI Severity of axonal injury was significantly reduced in the R18 (P = 0.02) and COG1410
(P = 0.05) treatment groups, while APP96-110 had no effect on axonal injury ( Figure   6 ). In the absence of injury, axons within the corpus callosum appeared smooth and well-organised, with oligodendrocyte nuclei arranged parallel to axons (Figure 7a ). [4, 7, 26] , and that calcium influx inhibition is influenced by peptide cationic charge and arginine content [5, 7] .
In the in vivo study, administration of Data are presented as mean ± SEM. There were no significant differences between vehicle and peptide treatment groups.
Translational Neuroscience Furthermore, the toxic increase in neuronal intracellular calcium can subsequently increase mitochondrial calcium levels with detrimental effects on the organelle, which ultimately lead to cell death [31, 32] . Consequently, given the capacity of R18 and COG1410 to reduce excitotoxicity-induced neuronal intracellular calcium, in addition to the known ability of CARPs to target and exert positive effects on mitochondria [20, 33, 34] , this could explain the observed positive effects on axonal injury. peptide is purported to act mainly via its heparin-binding activity [12] , however its exact mechanism has not been elucidated. A similar peptide also derived from the amyloid precursor protein suggests that APP96-110 could modulate calcium influx and activate NFκβ transcription factors [36] . Similarly, COG1410 may also affect calcium influx [37] through interactions with cell-surface heparan sulfate proteoglycans during internalisation into the cell [38] , but it is generally argued that its neuroprotective action is mainly through interactions with the lipoprotein receptorassociated protein [39] . In light of these reports and the findings of the present study, charge +3) has demonstrated histological and functional benefits in a closed-head TBI model [40] . In addition, the CN-105 peptide has also demonstrated efficacy in in vivo models of stroke [41] and intracerebral haemorrhage [42] .
While the in vivo study uncovered potential therapeutic effects with R18 and COG1410, several difficulties were encountered with the animal functional assessment procedures.
With regards to the rotarod assessment, it was observed that with repeated exposure, rats had a tendency to leap off the rotating rod during the test, leading to a shorter recorded latency. 
